Parkinson Disease Clinical Trials in Nashville, Tennessee

12 studies are recruiting for parkinson disease in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

   The purpose of this study is to determine the changes in quality of life and degree of tremor for patients with essential tremor or Parkinsonian tremor who are treated by stereotactic radiosurgery (SRS). This is a questionnaire-based study. Please see Detailed Description below for more information.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT01734122 on ClinicalTrials.gov

2. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

   This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. P…

   Stage

   Phase 2

   Ages

   30 to 80

   Site

   Vanderbilt University Medical Center (Site #204), Nashville, Tennessee

   Locations

   30 in total

   Run by

   Appello Pharmaceuticals, Inc.

   See if you can join NCT07432958 on ClinicalTrials.gov

3. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

   The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic p…

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Vanderbilt University, Nashville, Tennessee

   Locations

   72 in total

   Run by

   Neuron23 Inc.

   See if you can join NCT06680830 on ClinicalTrials.gov

4. Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

   It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18…

   Stage

   Phase 4

   Ages

   50 to 85

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT05357612 on ClinicalTrials.gov

5. A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

   The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

   Stage

   Phase 2

   Ages

   45 to 75

   Site

   Vanderbilt University (Neurology), Nashville, Tennessee

   Locations

   46 in total

   Run by

   AskBio Inc

   See if you can join NCT06285643 on ClinicalTrials.gov

6. Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment

   The goal of this study is to learn more about the brain activity underlying Parkinson's disease cognitive impairment. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor sympt…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT04715984 on ClinicalTrials.gov

7. Neurophysiology of Reward Signaling in Parkinson's Disease

   The goal of this study is to learn more about the brain activity underlying Parkinson's disease risk taking and reward seeking behaviors. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity under…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT07409207 on ClinicalTrials.gov

8. Natural History Study of Synucleinopathies

   Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of moveme…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt Univeristy, Nashville, Tennessee

   Locations

   8 in total

   Run by

   NYU Langone Health

   See if you can join NCT01799915 on ClinicalTrials.gov

9. Use of CereGate Therapy for Freezing of Gait in PD

   A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.

   Stage

   Not phased

   Ages

   21 to 80

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   7 in total

   Run by

   CereGate Inc.

   See if you can join NCT05292794 on ClinicalTrials.gov

10. CPAP for the Treatment of Supine Hypertension

    This study aims to learn about the effects of continuous positive airway pressure (CPAP) on people with autonomic failure and high blood pressure when lying down (supine hypertension) to determine if it can be used to treat their high blood pressure during the night. CPAP (a widely used treatment f…

    Stage

    Not phased

    Ages

    40 to 80

    Site

    Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT05489575 on ClinicalTrials.gov

11. [18F]F-DOPA Imaging in Patients With Autonomic Failure

    Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and/or glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g. caudal to rost…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Daniel Claassen

    See if you can join NCT04246437 on ClinicalTrials.gov

12. Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

    The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt Univ…

    Stage

    Phase 1

    Ages

    40 to 80

    Site

    Autonomic Dysfunction Center/ Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT02897063 on ClinicalTrials.gov